Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115667 | 0.81 | ALDH1A1 (0.54) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL125015 | 0.80 | SOS1 (0.56) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL29410319 | 0.80 | SOS1 (0.56) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL28049747 | 0.79 | CA12 (0.51) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL27940186 | 0.79 | CA12 (0.51) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL27798771 | 0.79 | MAPT (0.54) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL11217880 | 0.77 | MAPT (0.51) | CA12MAPTALDH1A1SOS1MEN1 | |
| Ethylene Glycol SCHEMBL1538616 | 0.76 | MAPT (0.51) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL9153228 | 0.76 | RAB9A (0.55) | CA12MAPTALDH1A1SOS1MEN1 | |
| SCHEMBL1231746 | 0.76 | ALDH1A1 (0.50) | CA12MAPTALDH1A1SOS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922575-B1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | HARVARD COLLEGE (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3177147-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1753713-B1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | HARVARD COLLEGE (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2016022970-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| EP-2922575-A1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | President and Fellows of Harvard College (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014082065-A1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-05-30 | — | — | WO | disclosed |
| EP-2726467-A2 | MACROCYCLIC INSULIN-DEGRADING ENZYME (IDE) INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8586020-B2 | Poly(organophosphazene) composition for biomaterials | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| WO-2013006451-A2 | MACROCYCLIC INSULIN-DEGRADING ENZYME (IDE) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-10 | — | — | WO | disclosed |
| EP-2438046-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141074-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-1505156-B1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-02-10 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | LIPC, LIPE, LIPA | CA12 1466/4885MAPT 4496/4885ALDH1A1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.